AEON Biopharma Files 8-K on Security Holder Vote Matters
Ticker: AEON · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1837607
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, filing-update
TL;DR
AEON Biopharma holding shareholder vote - important decisions ahead.
AI Summary
AEON Biopharma, Inc. filed an 8-K on June 14, 2024, to report on the submission of matters to a vote of its security holders. The company, formerly known as Priveterra Acquisition Corp. until December 22, 2020, is incorporated in Delaware and headquartered in Irvine, California.
Why It Matters
This filing indicates that AEON Biopharma is engaging its shareholders on important corporate decisions, which could impact the company's future direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is procedural and reports on a shareholder vote, not a material adverse event.
Key Numbers
- 001-40021 — SEC File Number (Identifies the company's filing history with the SEC.)
- 85-3940478 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- AEON Biopharma, Inc. (company) — Registrant
- Priveterra Acquisition Corp. (company) — Former company name
- June 14, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Irvine, CA (location) — Principal Executive Offices
FAQ
What specific matters are being submitted for a vote of security holders?
The filing does not specify the exact matters to be voted on, only that matters are being submitted for a vote.
When was AEON Biopharma, Inc. formerly known as Priveterra Acquisition Corp.?
The company's name changed from Priveterra Acquisition Corp. on December 22, 2020.
What is the principal executive office address of AEON Biopharma, Inc.?
The principal executive offices are located at 5 Park Plaza, Suite 1750, Irvine, CA 92614.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 14, 2024.
Under which section of the Securities Exchange Act is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 707 words · 3 min read · ~2 pages · Grade level 13.7 · Accepted 2024-06-14 16:06:11
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share AEON NYSE Ameri
Filing Documents
- aeon-20240614x8k.htm (8-K) — 47KB
- 0001837607-24-000070.txt ( ) — 176KB
- aeon-20240614.xsd (EX-101.SCH) — 4KB
- aeon-20240614_def.xml (EX-101.DEF) — 3KB
- aeon-20240614_lab.xml (EX-101.LAB) — 17KB
- aeon-20240614_pre.xml (EX-101.PRE) — 10KB
- aeon-20240614x8k_htm.xml (XML) — 5KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. AEON Biopharma, Inc. (the "Company") held its Annual Meeting of Stockholders on June 14, 2024 (the "Annual Meeting") as described in the Company's proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission (the "SEC") on April 29, 2024, as amended with materials filed with the SEC on May 14, 2024 (the "2024 Proxy"). At the Annual Meeting, the stockholders of the Company voted on three proposals as further described in the 2024 Proxy. The final results for each proposal voted on by the stockholders at the Annual Meeting, as certified by the Company's inspector of elections, are set forth below. Proposal 1 : The stockholders of the Company elected each of Robert Palmisano and Shelley Thunen as Class I directors of the Company's board of directors (the "Class I Directors") for a three-year term ending at the Annual Meeting of Stockholders to be held in 2027 and until each of their successors has been duly elected and qualified. The voting results with respect to the election of the Class I Directors were as follows: Nominee Term Expiring For Withheld Broker Non-Vote Robert Palmisano 2027 24,463,654 399,588 675,301 Shelley Thunen 2027 24,431,564 431,678 675,301 Proposal 2 : The stockholders of the Company approved a potential issuance to Daewoong Pharmaceuticals Co. LTD. of the Company's Class A common stock, par value $0.0001 ("Common Stock"), or securities convertible into Common Stock, equal to 20% or more of the Company's presently outstanding stock for less than the greater of book or market value of the stock for purposes of Section 713(a)(ii) of the New York Stock Exchange American LLC ("NYSE American") Listed Company Guide ("LCG") and as a "change of control" of the Company for purposes of Section 713(b) of the NYSE American LCG. The voting results for this proposal were as follows: For Against Abstain Broker Non-Vote 24,383,900 470,79